Brands often focus on market share against direct competitors. However, the real competition can be invisible factors like a patient's belief system, inertia, or logistical hurdles in the healthcare system that cause them to delay or abandon treatment altogether.

Most GTM systems track initial outreach and final outcomes but fail to quantify the critical journey in between. This "ginormous gray area" of engagement makes it impossible to understand which activities truly influence pipeline, leading to flawed, outcome-based decision-making instead of journey-based optimization.

While ensuring patient access through co-pay cards and prior authorizations was once the primary focus, it has now become table stakes. Leading pharmaceutical companies are shifting investment toward perfecting the 'day one' experience, recognizing that a poor initial self-administration can lead to immediate therapy abandonment.

Consumers use wellness apps, AI, and health trackers, giving them a false sense of being informed about their health. This creates a new gap where feeling well or having data is substituted for actual clinical evaluation, delaying necessary medical care, especially for silent diseases.

Healthcare systems invest heavily in diagnosis but then abandon patients once a prescription is handed over. This "disconnection point" leads to medication non-adherence and confusion, as the patient's actual healing journey is just beginning and requires ongoing support.

By analyzing real-world data with machine learning, Walgreens can identify patients at risk of non-adherence before a clinical issue arises. This allows for early, personalized interventions, moving beyond simply reacting to missed doses or therapy drop-offs.

Despite generating enormous amounts of data from hubs, specialty pharmacies, and copay programs, the data remains siloed. This fragmentation prevents a holistic patient view, leading to poor decision-making, patient non-adherence, and significant avoidable healthcare costs.

Instead of focusing solely on quarterly revenue, a successful rare disease launch was measured by KPIs like the number of patients identified and the speed of early intervention. These patient-focused metrics served as leading indicators that ultimately translated into commercial success and a stronger external narrative.

The massive abandonment rate of health apps stems from a core design flaw: they are built to achieve company objectives (e.g., increase diagnosis) rather than integrating into patients' and doctors' existing workflows and behaviors, making them burdensome to use.